Spotlight on Pediatrics
Influenza: Reducing Complications in High-Risk Patients Through Advanced Treatment Options – Curbside Consult: An Adult Patient With Asthma and Symptoms of Flu
StartActivity Details
/ABIM MOC
Expires: June 28, 2021
Accredited By
This continuing medical education activity is provided by
Target Audience
The intended audience for the activity is allergists, immunologists, family practice physicians, general practice physicians, internists, pulmonologists, nurse practitioners, physician assistants, and other health care professionals involved in the management of patients with influenza.
Learning Objectives
Upon successful completion of the activity, participants should be better able to:
- Incorporate revised guidelines into practice to improve earlier detection and treatment of patients with influenza and comorbid respiratory conditions.
- Compare influenza antiviral treatments in terms of their efficacy, safety, and ability to reduce viral shedding and infection in others.
- Incorporate the most appropriate therapeutic regimen in patients with influenza who are at high risk for complications.
Activity Description
In this educational program, expert faculty will discuss strategies for incorporating the latest information regarding the diagnosis and treatment of influenza into practice. Using challenging case-based examples, faculty will provide guidance on selecting the most appropriate therapeutic regimen to reduce morbidity and mortality in patients with influenza who are at high risk for complications.
Faculty
Paul G. Auwaerter, MD, MBA, FIDSA
Sherrilyn and Ken Fisher Professor of Medicine
Clinical Director, Division of Infectious Diseases
Director, Sherrilyn and Ken Fisher Center for Environmental Infectious Diseases
Johns Hopkins University School of Medicine
Baltimore, MD
- Disclosure:
- Consulting Fee: Advanced Biotherapeutics, DiaSorin
- Ownership Interest: Johnson & Johnson
John J. Russell, MD
Clinical Professor of Family and Community Medicine
Thomas Jefferson University
Sidney Kimmel School of Medicine
Philadelphia, PA
Chair, Department of Family Medicine
Program Director, Family Medicine Residency
Abington – Jefferson Health
Abington, PA
- Disclosure:
- Consulting Fee: GlaxoSmithKline, Sanofi Pasteur
- Speakers Bureau: Sanofi Pasteur
Reviewers:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to
disclose.
Ronald A. Codario, Jr., MD
Disclosure: No relevant financial relationships to
disclose.
Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to
disclose.
Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Agenda
Curbside Consult: An Adult Patient With Asthma and Symptoms of
Flu
Paul G. Auwaerter, MD, MBA, FIDSA and John J. Russell, MD
Conflict of Interest Policy/Disclosure Statement
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information appears above.
Accreditation Statement
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Designation of Credit
Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this
CME activity enables the participant to earn up to 0.25 MOC points in the
American Board of Internal Medicine’s (ABIM) Maintenance of Certification
(MOC) program. Participants who opt-in will earn MOC points equivalent to the
amount of CME credits claimed for the activity. It is the CME activity
provider’s responsibility to submit participant completion information to
ACCME for the purpose of granting ABIM MOC points.
Nurse practitioners can apply for AMA PRA Category 1 Credit(s)™ through the American Academy of Nurse Practitioners Certification Board (AANPCB). AANPCB will accept AMA PRA Category 1 Credit(s)™ from organizations accredited by Accreditation Council for Continuing Medical Education.
Physician assistants participating in the enduring activity can apply for AMA PRA Category 1 Credit(s)™ through the American Academy of Physician Assistants (AAPA). AAPA will accept AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME.
Instructions for Receiving Credit
To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.
Statement of Commercial Support
This activity is supported by an educational grant from Genentech, Inc.
Disclaimer Statement/Disclosure of Unlabeled Use
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non‒FDA-approved or investigational use of products/devices.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road,
Building 100, Thorofare, NJ
CME Questions?
Contact us at CME@VindicoCME.com
Activity Details
/ABIM MOC
Expires: June 28, 2021
Accredited By
This continuing medical education activity is provided by
Target Audience
The intended audience for the activity is allergists, immunologists, family practice physicians, general practice physicians, internists, pulmonologists, nurse practitioners, physician assistants, and other health care professionals involved in the management of patients with influenza.
Learning Objectives
Upon successful completion of the activity, participants should be better able to:
- Incorporate revised guidelines into practice to improve earlier detection and treatment of patients with influenza and comorbid respiratory conditions.
- Compare influenza antiviral treatments in terms of their efficacy, safety, and ability to reduce viral shedding and infection in others.
- Incorporate the most appropriate therapeutic regimen in patients with influenza who are at high risk for complications.
Activity Description
In this educational program, expert faculty will discuss strategies for incorporating the latest information regarding the diagnosis and treatment of influenza into practice. Using challenging case-based examples, faculty will provide guidance on selecting the most appropriate therapeutic regimen to reduce morbidity and mortality in patients with influenza who are at high risk for complications.
Faculty
Paul G. Auwaerter, MD, MBA, FIDSA
Sherrilyn and Ken Fisher Professor of Medicine
Clinical Director, Division of Infectious Diseases
Director, Sherrilyn and Ken Fisher Center for Environmental Infectious Diseases
Johns Hopkins University School of Medicine
Baltimore, MD
- Disclosure:
- Consulting Fee: Advanced Biotherapeutics, DiaSorin
- Ownership Interest: Johnson & Johnson
John J. Russell, MD
Clinical Professor of Family and Community Medicine
Thomas Jefferson University
Sidney Kimmel School of Medicine
Philadelphia, PA
Chair, Department of Family Medicine
Program Director, Family Medicine Residency
Abington – Jefferson Health
Abington, PA
- Disclosure:
- Consulting Fee: GlaxoSmithKline, Sanofi Pasteur
- Speakers Bureau: Sanofi Pasteur
Reviewers:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to
disclose.
Ronald A. Codario, Jr., MD
Disclosure: No relevant financial relationships to
disclose.
Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to
disclose.
Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Agenda
Curbside Consult: An Adult Patient With Asthma and Symptoms of
Flu
Paul G. Auwaerter, MD, MBA, FIDSA and John J. Russell, MD
Conflict of Interest Policy/Disclosure Statement
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information appears above.
Accreditation Statement
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Designation of Credit
Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this
CME activity enables the participant to earn up to 0.25 MOC points in the
American Board of Internal Medicine’s (ABIM) Maintenance of Certification
(MOC) program. Participants who opt-in will earn MOC points equivalent to the
amount of CME credits claimed for the activity. It is the CME activity
provider’s responsibility to submit participant completion information to
ACCME for the purpose of granting ABIM MOC points.
Nurse practitioners can apply for AMA PRA Category 1 Credit(s)™ through the American Academy of Nurse Practitioners Certification Board (AANPCB). AANPCB will accept AMA PRA Category 1 Credit(s)™ from organizations accredited by Accreditation Council for Continuing Medical Education.
Physician assistants participating in the enduring activity can apply for AMA PRA Category 1 Credit(s)™ through the American Academy of Physician Assistants (AAPA). AAPA will accept AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME.
Instructions for Receiving Credit
To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.
Statement of Commercial Support
This activity is supported by an educational grant from Genentech, Inc.
Disclaimer Statement/Disclosure of Unlabeled Use
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non‒FDA-approved or investigational use of products/devices.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road,
Building 100, Thorofare, NJ
CME Questions?
Contact us at CME@VindicoCME.com
Pediatrics Presentations
Gene Therapy for SMA: Data, Implications, and Global Perspectives — Importance of Early Diagnosis and Screening in SMA
StartActivity Details
Expires: September 30, 2021
Accredited By
Target Audience
This activity will target neurologists, pediatricians, and geneticists, as well as other health care providers who may be involved in the management of patients with SMA.
Learning Objectives
- Explore potential implications of gene therapy for SMA
Activity Description
This activity discusses new, emerging, and targeted treatments for SMA. The activity also explores the potential clinical challenges and how this affects phenotypes over time.
Statement of Educational Need
The rapid influx of information surrounding emerging treatments for SMA means that there are critical gaps in clinician knowledge and the ability to apply it in practice, creating a need for education to support clinicians who recognize, diagnose, and/or manage patients with SMA.
Faculty
Director of SMA Therapies,
Schneider Institute of Child Neurology Children’s Medical Center
Petach Tikva, Israel
Sharon Aharoni, MD, has participated in contract research for AveXis.
Unit of Neuromuscular and Neurodegenerative Disorders
Laboratory of Molecular Medicine
Bambino Gesu' Children's Research Hospital
Rome, Italy
Professor Enrico Bertini has no financial relationships to disclose.
Director, Pediatric Neurology Institute
Dana Children's Hospital, Tel Aviv Medical Center
Tel Aviv, Israel
Professor Aviva Fattal-Valevski has no financial relationships to disclose.
Assistant Professor of Neurology
The University of Campinas
Sao Paulo, Brazil
Professor Marcondes Cavalcante França Junior has participated in advisory boards for AveXis, Biogen, and Roche.
Head of Center for Pediatric Neuromuscular Disorders
and Clinical Neurophysiology
Dr. von Hauner Children’s Hospital
Munich, Germany
Professor Wolfgang Mueller-Felber has participated in scientific advisory boards for Genzyme and has received research support from GlaxoSmithKline, Lilly, and Trophos.
Attending Physician
Institut de Myologie
Paris, France
J. Andoni Urtizberea, MD, MSc, has no financial relationships to disclose.
Conflict of Interest Policy/Disclosure Statement
In accordance with the ACCME Standards for Commercial Support, The France Foundation (TFF) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TFF resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs. Furthermore, TFF seeks to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF is committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.
Accreditation Statement
The France Foundation is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation of Credit
Physicians
The France Foundation designates this enduring activity for a maximum of
0.25 AMA PRA Category 1 Credit(s)™. Physicians
should claim only the credit commensurate with the extent of their
participation in the activity.
Nurses
Nurses who are certified by the American Nurses Credentialing Center (ANCC)
may utilize activities that are certified by ACCME-accredited providers
toward their requirement for certification renewal by the ANCC. A certificate
of attendance will be provided by The France Foundation, an ACCME accredited
provider.
Method of Participation/How to Receive Credit
- There are no fees for participating in and receiving credit for this activity.
- Review the activity objectives and CME/CE information.
- Complete the CME/CE activity.
- Complete the online posttest. A score of at least 66% is required to complete this activity. The participant may take the test until successfully passed.
- Complete the CME/CE evaluation/attestation form. The form provides each participant the opportunity to comment on how the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and his/her views on future educational needs.
- Credit documentation/reporting:
-
- If you are requesting AMA PRA Category 1 Credits™ or a certificate of participation—your CME/CE certificate will be available for download.
Statement of Commercial Support
This activity is supported by an educational grant from AveXis.
Disclaimer Statement/Disclosure of Unlabeled Use
The France Foundation presents this information for educational purposes only. The content is provided solely by faculty who have been selected because of their recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The France Foundation and the commercial supporter(s) assume no liability for the information herein.
Contact Information for Questions About the Activity
If you have questions about this CME activity, please contact The France Foundation at 860-434-1650 or info@francefoundation.com.
Activity Details
Expires: September 30, 2021
Accredited By
Target Audience
This activity will target neurologists, pediatricians, and geneticists, as well as other health care providers who may be involved in the management of patients with SMA.
Learning Objectives
- Explore potential implications of gene therapy for SMA
Activity Description
This activity discusses new, emerging, and targeted treatments for SMA. The activity also explores the potential clinical challenges and how this affects phenotypes over time.
Statement of Educational Need
The rapid influx of information surrounding emerging treatments for SMA means that there are critical gaps in clinician knowledge and the ability to apply it in practice, creating a need for education to support clinicians who recognize, diagnose, and/or manage patients with SMA.
Faculty
Director of SMA Therapies,
Schneider Institute of Child Neurology Children’s Medical Center
Petach Tikva, Israel
Sharon Aharoni, MD, has participated in contract research for AveXis.
Unit of Neuromuscular and Neurodegenerative Disorders
Laboratory of Molecular Medicine
Bambino Gesu' Children's Research Hospital
Rome, Italy
Professor Enrico Bertini has no financial relationships to disclose.
Director, Pediatric Neurology Institute
Dana Children's Hospital, Tel Aviv Medical Center
Tel Aviv, Israel
Professor Aviva Fattal-Valevski has no financial relationships to disclose.
Assistant Professor of Neurology
The University of Campinas
Sao Paulo, Brazil
Professor Marcondes Cavalcante França Junior has participated in advisory boards for AveXis, Biogen, and Roche.
Head of Center for Pediatric Neuromuscular Disorders
and Clinical Neurophysiology
Dr. von Hauner Children’s Hospital
Munich, Germany
Professor Wolfgang Mueller-Felber has participated in scientific advisory boards for Genzyme and has received research support from GlaxoSmithKline, Lilly, and Trophos.
Attending Physician
Institut de Myologie
Paris, France
J. Andoni Urtizberea, MD, MSc, has no financial relationships to disclose.
Conflict of Interest Policy/Disclosure Statement
In accordance with the ACCME Standards for Commercial Support, The France Foundation (TFF) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TFF resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs. Furthermore, TFF seeks to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF is committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.
Accreditation Statement
The France Foundation is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation of Credit
Physicians
The France Foundation designates this enduring activity for a maximum of
0.25 AMA PRA Category 1 Credit(s)™. Physicians
should claim only the credit commensurate with the extent of their
participation in the activity.
Nurses
Nurses who are certified by the American Nurses Credentialing Center (ANCC)
may utilize activities that are certified by ACCME-accredited providers
toward their requirement for certification renewal by the ANCC. A certificate
of attendance will be provided by The France Foundation, an ACCME accredited
provider.
Method of Participation/How to Receive Credit
- There are no fees for participating in and receiving credit for this activity.
- Review the activity objectives and CME/CE information.
- Complete the CME/CE activity.
- Complete the online posttest. A score of at least 66% is required to complete this activity. The participant may take the test until successfully passed.
- Complete the CME/CE evaluation/attestation form. The form provides each participant the opportunity to comment on how the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and his/her views on future educational needs.
- Credit documentation/reporting:
-
- If you are requesting AMA PRA Category 1 Credits™ or a certificate of participation—your CME/CE certificate will be available for download.
Statement of Commercial Support
This activity is supported by an educational grant from AveXis.
Disclaimer Statement/Disclosure of Unlabeled Use
The France Foundation presents this information for educational purposes only. The content is provided solely by faculty who have been selected because of their recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The France Foundation and the commercial supporter(s) assume no liability for the information herein.
Contact Information for Questions About the Activity
If you have questions about this CME activity, please contact The France Foundation at 860-434-1650 or info@francefoundation.com.
Gene Therapy for SMA: Data, Implications, and Global Perspectives — SMA: Introduction and Key Concepts
StartActivity Details
Expires: September 30, 2021
Accredited By
Target Audience
This activity will target neurologists, pediatricians, and geneticists, as well as other health care providers who may be involved in the management of patients with SMA.
Learning Objectives
- Describe criteria for SMA diagnosis
- Describe how SMA diagnosis can be missed or delayed
Activity Description
This education focuses on the early diagnosis and treatment of SMA and the importance of newborn screening. Pre-symptomatic treatment of SMA can dramatically change the disease course and newborn screening is crucial to early detection and early treatment.
Statement of Educational Need
The rapid influx of information surrounding emerging treatments for SMA means that there are critical gaps in clinician knowledge and the ability to apply it in practice, creating a need for education to support clinicians who recognize, diagnose, and/or manage patients with SMA.
Faculty
Director of SMA Therapies,
Schneider Institute of Child Neurology Children’s Medical Center
Petach Tikva, Israel
Sharon Aharoni, MD, has participated in contract research for AveXis.
Unit of Neuromuscular and Neurodegenerative Disorders
Laboratory of Molecular Medicine
Bambino Gesu' Children's Research Hospital
Rome, Italy
Professor Enrico Bertini has no financial relationships to disclose.
Director, Pediatric Neurology Institute
Dana Children's Hospital, Tel Aviv Medical Center
Tel Aviv, Israel
Professor Aviva Fattal-Valevski has no financial relationships to disclose.
Assistant Professor of Neurology
The University of Campinas
Sao Paulo, Brazil
Professor Marcondes Cavalcante França Junior has participated in advisory boards for AveXis, Biogen, and Roche.
Head of Center for Pediatric Neuromuscular Disorders
and Clinical Neurophysiology
Dr. von Hauner Children’s Hospital
Munich, Germany
Professor Wolfgang Mueller-Felber has participated in scientific advisory boards for Genzyme and has received research support from GlaxoSmithKline, Lilly, and Trophos.
Attending Physician
Institut de Myologie
Paris, France
J. Andoni Urtizberea, MD, MSc, has no financial relationships to disclose.
Conflict of Interest Policy/Disclosure Statement
In accordance with the ACCME Standards for Commercial Support, The France Foundation (TFF) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TFF resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs. Furthermore, TFF seeks to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF is committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.
Accreditation Statement
The France Foundation is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation of Credit
Physicians
The France Foundation designates this enduring activity for a maximum of
0.25 AMA PRA Category 1 Credit(s)™. Physicians
should claim only the credit commensurate with the extent of their
participation in the activity.
Nurses
Nurses who are certified by the American Nurses Credentialing Center (ANCC)
may utilize activities that are certified by ACCME-accredited providers
toward their requirement for certification renewal by the ANCC. A certificate
of attendance will be provided by The France Foundation, an ACCME accredited
provider.
Method of Participation/How to Receive Credit
- There are no fees for participating in and receiving credit for this activity.
- Review the activity objectives and CME/CE information.
- Complete the CME/CE activity.
- Complete the online posttest. A score of 100% is required to complete this activity. The participant may take the test until successfully passed.
- Complete the CME/CE evaluation/attestation form. The form provides each participant the opportunity to comment on how the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and his/her views on future educational needs.
- Credit documentation/reporting:
-
- If you are requesting AMA PRA Category 1 Credits™ or a certificate of participation—your CME/CE certificate will be available for download.
Statement of Commercial Support
This activity is supported by an educational grant from AveXis.
Disclaimer Statement/Disclosure of Unlabeled Use
The France Foundation presents this information for educational purposes only. The content is provided solely by faculty who have been selected because of their recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The France Foundation and the commercial supporter(s) assume no liability for the information herein.
Contact Information for Questions About the Activity
If you have questions about this CME activity, please contact The France Foundation at 860-434-1650 or info@francefoundation.com.
Activity Details
Expires: September 30, 2021
Accredited By
Target Audience
This activity will target neurologists, pediatricians, and geneticists, as well as other health care providers who may be involved in the management of patients with SMA.
Learning Objectives
- Describe criteria for SMA diagnosis
- Describe how SMA diagnosis can be missed or delayed
Activity Description
This education focuses on the early diagnosis and treatment of SMA and the importance of newborn screening. Pre-symptomatic treatment of SMA can dramatically change the disease course and newborn screening is crucial to early detection and early treatment.
Statement of Educational Need
The rapid influx of information surrounding emerging treatments for SMA means that there are critical gaps in clinician knowledge and the ability to apply it in practice, creating a need for education to support clinicians who recognize, diagnose, and/or manage patients with SMA.
Faculty
Director of SMA Therapies,
Schneider Institute of Child Neurology Children’s Medical Center
Petach Tikva, Israel
Sharon Aharoni, MD, has participated in contract research for AveXis.
Unit of Neuromuscular and Neurodegenerative Disorders
Laboratory of Molecular Medicine
Bambino Gesu' Children's Research Hospital
Rome, Italy
Professor Enrico Bertini has no financial relationships to disclose.
Director, Pediatric Neurology Institute
Dana Children's Hospital, Tel Aviv Medical Center
Tel Aviv, Israel
Professor Aviva Fattal-Valevski has no financial relationships to disclose.
Assistant Professor of Neurology
The University of Campinas
Sao Paulo, Brazil
Professor Marcondes Cavalcante França Junior has participated in advisory boards for AveXis, Biogen, and Roche.
Head of Center for Pediatric Neuromuscular Disorders
and Clinical Neurophysiology
Dr. von Hauner Children’s Hospital
Munich, Germany
Professor Wolfgang Mueller-Felber has participated in scientific advisory boards for Genzyme and has received research support from GlaxoSmithKline, Lilly, and Trophos.
Attending Physician
Institut de Myologie
Paris, France
J. Andoni Urtizberea, MD, MSc, has no financial relationships to disclose.
Conflict of Interest Policy/Disclosure Statement
In accordance with the ACCME Standards for Commercial Support, The France Foundation (TFF) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TFF resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs. Furthermore, TFF seeks to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF is committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.
Accreditation Statement
The France Foundation is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation of Credit
Physicians
The France Foundation designates this enduring activity for a maximum of
0.25 AMA PRA Category 1 Credit(s)™. Physicians
should claim only the credit commensurate with the extent of their
participation in the activity.
Nurses
Nurses who are certified by the American Nurses Credentialing Center (ANCC)
may utilize activities that are certified by ACCME-accredited providers
toward their requirement for certification renewal by the ANCC. A certificate
of attendance will be provided by The France Foundation, an ACCME accredited
provider.
Method of Participation/How to Receive Credit
- There are no fees for participating in and receiving credit for this activity.
- Review the activity objectives and CME/CE information.
- Complete the CME/CE activity.
- Complete the online posttest. A score of 100% is required to complete this activity. The participant may take the test until successfully passed.
- Complete the CME/CE evaluation/attestation form. The form provides each participant the opportunity to comment on how the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and his/her views on future educational needs.
- Credit documentation/reporting:
-
- If you are requesting AMA PRA Category 1 Credits™ or a certificate of participation—your CME/CE certificate will be available for download.
Statement of Commercial Support
This activity is supported by an educational grant from AveXis.
Disclaimer Statement/Disclosure of Unlabeled Use
The France Foundation presents this information for educational purposes only. The content is provided solely by faculty who have been selected because of their recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The France Foundation and the commercial supporter(s) assume no liability for the information herein.
Contact Information for Questions About the Activity
If you have questions about this CME activity, please contact The France Foundation at 860-434-1650 or info@francefoundation.com.
Improving Adult Vaccine Confidence: A GameOn! Challenge
StartActivity Details
/ABIM MOC
Expires: August 5, 2021
Accredited By
This continuing medical education activity is provided by
Target Audience
The intended audience for this activity is internists and other health care professionals involved in the management of patients in need of vaccines.
Learning Objectives
Upon successful completion of this activity, participants should be better able to:
- Review the safe and effective use of vaccination in high-risk patients, such as those who are aged 65 years or older, have significant comorbidities, or are immunocompromised.
- Recommend vaccines to adult patients in accordance with the latest ACIP recommendations.
- Use effective strategies to educate adult patients and increase their vaccine confidence.
Activity Description
Vaccines prevent 2 to 3 million deaths per year, yet compliance with Advisory Committee on Immunization Practices (ACIP) recommendations remains low in the United States. Recently, the Centers for Disease Control and Prevention issued a program, Vaccinate with Confidence, to protect communities at risk and strengthen public trust in vaccination. Central to this program is the need to debunk vaccine myths via education and family empowerment. In this CME activity, participants will play GameOn!, a quiz of knowledge and confidence, in which they will answer questions on the latest ACIP recommendations regarding high-risk patients and vaccination strategies for adult patients and select the level of confidence in their answers to achieve the highest score among their peers.
Faculty
Charles P. Vega, MD, FAAFP
Health Sciences Clinical Professor,
Department of Family Medicine
Executive Director,
Program in Medical Education for the Latino Community
Assistant Dean for Culture and Community Education
University of California, Irvine
Irvine, CA
Disclosure: No relevant financial relationships to disclose.
Reviewers:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
- Disclosure: No relevant financial relationships to disclose.
Ronald A. Codario, Jr., MD
- Disclosure: No relevant financial relationships to disclose.
Vindico Medical Education Staff:
- Disclosure: No relevant financial relationships to disclose.
Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Conflict of Interest Policy/Disclosure Statement
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information appears above.
Accreditation Statement
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Designation of Credit
Vindico Medical Education designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this
CME activity enables the participant to earn up to 0.5 MOC points in the
American Board of Internal Medicine’s (ABIM) Maintenance of Certification
(MOC) program. Participants who opt-in will earn MOC points equivalent to the
amount of CME credits claimed for the activity. It is the CME activity
provider’s responsibility to submit participant completion information to
ACCME for the purpose of granting ABIM MOC points.
Instructions for Receiving Credit
To participate in this CME activity, you must read the objectives, answer the pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for the questions. A satisfactory score is defined as answering 66% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.
Statement of Commercial Support
This activity is supported by an educational grant from Merck & Co., Inc.
Disclaimer Statement/Disclosure of Unlabeled Use
The audience is advised that this continuing education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CME Questions?
Contact us at CME@VindicoCME.com
Activity Details
/ABIM MOC
Expires: August 5, 2021
Accredited By
This continuing medical education activity is provided by
Target Audience
The intended audience for this activity is internists and other health care professionals involved in the management of patients in need of vaccines.
Learning Objectives
Upon successful completion of this activity, participants should be better able to:
- Review the safe and effective use of vaccination in high-risk patients, such as those who are aged 65 years or older, have significant comorbidities, or are immunocompromised.
- Recommend vaccines to adult patients in accordance with the latest ACIP recommendations.
- Use effective strategies to educate adult patients and increase their vaccine confidence.
Activity Description
Vaccines prevent 2 to 3 million deaths per year, yet compliance with Advisory Committee on Immunization Practices (ACIP) recommendations remains low in the United States. Recently, the Centers for Disease Control and Prevention issued a program, Vaccinate with Confidence, to protect communities at risk and strengthen public trust in vaccination. Central to this program is the need to debunk vaccine myths via education and family empowerment. In this CME activity, participants will play GameOn!, a quiz of knowledge and confidence, in which they will answer questions on the latest ACIP recommendations regarding high-risk patients and vaccination strategies for adult patients and select the level of confidence in their answers to achieve the highest score among their peers.
Faculty
Charles P. Vega, MD, FAAFP
Health Sciences Clinical Professor,
Department of Family Medicine
Executive Director,
Program in Medical Education for the Latino Community
Assistant Dean for Culture and Community Education
University of California, Irvine
Irvine, CA
Disclosure: No relevant financial relationships to disclose.
Reviewers:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
- Disclosure: No relevant financial relationships to disclose.
Ronald A. Codario, Jr., MD
- Disclosure: No relevant financial relationships to disclose.
Vindico Medical Education Staff:
- Disclosure: No relevant financial relationships to disclose.
Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Conflict of Interest Policy/Disclosure Statement
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information appears above.
Accreditation Statement
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Designation of Credit
Vindico Medical Education designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this
CME activity enables the participant to earn up to 0.5 MOC points in the
American Board of Internal Medicine’s (ABIM) Maintenance of Certification
(MOC) program. Participants who opt-in will earn MOC points equivalent to the
amount of CME credits claimed for the activity. It is the CME activity
provider’s responsibility to submit participant completion information to
ACCME for the purpose of granting ABIM MOC points.
Instructions for Receiving Credit
To participate in this CME activity, you must read the objectives, answer the pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for the questions. A satisfactory score is defined as answering 66% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.
Statement of Commercial Support
This activity is supported by an educational grant from Merck & Co., Inc.
Disclaimer Statement/Disclosure of Unlabeled Use
The audience is advised that this continuing education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CME Questions?
Contact us at CME@VindicoCME.com
Advancing Diagnosis and Individualized Treatment of Severe Asthma Through Application of Guidelines and Latest Evidence
StartActivity Details
Expires: July 22, 2021
Accredited By
Target Audience
This educational initiative has been designed for allergists, pulmonologists, fellows, and internal medicine physicians involved in the management of patients with severe asthma.
Learning Objectives
- Demonstrate the ability to diagnose patients with severe versus difficult-to-treat versus persistent uncontrolled asthma
- Describe the risks of OCS overuse and summarize strategies to reduce OCS use in severe asthma
- Employ biomarker testing in the evaluation of severe asthma and utilize results to classify patients with severe asthma
- Develop personalized treatment plans for patients with severe asthma that are consistent with current evidence-based recommendations
Activity Description
Interactive Puzzle Activity
Statement of Educational Need
Severe asthma remains a disease with a high economic, healthcare, and patient burden. Patients with severe asthma suffer frequent exacerbations and the unpredictability of their disease. Prior to the availability of newer therapies that provide an opportunity to improve the management of patients with severe asthma, many patients relied on oral corticosteroids (OCS) as a mainstay of treatment. In fact, Cataldo et al. reported in 2020 that many patients with severe asthma were self-medicating with OCS during episodes of worsening symptoms or as prevention of such episodes in addition to physician-diagnosed exacerbation management. The utility of new therapies is underscored by the need for clinicians to be competent to make an efficient and accurate diagnosis and classification of severe asthma, to possess knowledge of recently released guidelines for severe asthma management, and to be able to select appropriate individualized therapy based on patient profiles and desires. This program has been designed to ensure that fellows and post-specialty-trained clinicians are able to meet the needs of the diverse population of severe asthma patients and design effective treatment plans to reduce symptoms, exacerbations, and the continued need for OCS in patients with severe asthma.
Faculty
Professor of Medicine
Robert Wood Johnson Medical School
Vice Chancellor, Clinical & Translational Science
Director, Rutgers Institute for Translational Medicine & Science
New Brunswick, New Jersey
Emeritus Professor of Medicine
University of Pennsylvania
Philadelphia, Pennsylvania
Conflict of Interest Policy/Disclosure Statement
Integrity Continuing Education requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:
Reynold A. Panettieri, Jr., MD
Consulting Fees: AstraZeneca, MedImmune, RIFM, Equillium, Theravance
Speakers’ Bureaus: AstraZeneca, Sanofi, Genentech
Contracted Research: AstraZeneca, MedImmune, RIFM, Genentech, OncoArendi
Patima Tanapat, PhD, hereby states that she or her spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
Accreditation Statement
Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Designation of Credit
Integrity Continuing Education, Inc. designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Instructions for Receiving Credit
There are no fees for participating and receiving CME credit for this activity. During the period of July 22, 2020 through July 22, 2021, participants must:
- Read the learning objectives and faculty disclosures
- Complete the pretest
- Study the educational activity
- Complete the posttest and the evaluation form
A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. and Sanofi Genzyme and Regeneron Pharmaceuticals do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
The information provided in this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient's medical condition.
Contact Information for Questions About the Activity
For information about ACCME accreditation of this activity, please contact Integrity Continuing Education at (855) 835-4004 or info@integrityce.com.
Statement of Commercial Support
Supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.
Activity Details
Expires: July 22, 2021
Accredited By
Target Audience
This educational initiative has been designed for allergists, pulmonologists, fellows, and internal medicine physicians involved in the management of patients with severe asthma.
Learning Objectives
- Demonstrate the ability to diagnose patients with severe versus difficult-to-treat versus persistent uncontrolled asthma
- Describe the risks of OCS overuse and summarize strategies to reduce OCS use in severe asthma
- Employ biomarker testing in the evaluation of severe asthma and utilize results to classify patients with severe asthma
- Develop personalized treatment plans for patients with severe asthma that are consistent with current evidence-based recommendations
Activity Description
Interactive Puzzle Activity
Statement of Educational Need
Severe asthma remains a disease with a high economic, healthcare, and patient burden. Patients with severe asthma suffer frequent exacerbations and the unpredictability of their disease. Prior to the availability of newer therapies that provide an opportunity to improve the management of patients with severe asthma, many patients relied on oral corticosteroids (OCS) as a mainstay of treatment. In fact, Cataldo et al. reported in 2020 that many patients with severe asthma were self-medicating with OCS during episodes of worsening symptoms or as prevention of such episodes in addition to physician-diagnosed exacerbation management. The utility of new therapies is underscored by the need for clinicians to be competent to make an efficient and accurate diagnosis and classification of severe asthma, to possess knowledge of recently released guidelines for severe asthma management, and to be able to select appropriate individualized therapy based on patient profiles and desires. This program has been designed to ensure that fellows and post-specialty-trained clinicians are able to meet the needs of the diverse population of severe asthma patients and design effective treatment plans to reduce symptoms, exacerbations, and the continued need for OCS in patients with severe asthma.
Faculty
Professor of Medicine
Robert Wood Johnson Medical School
Vice Chancellor, Clinical & Translational Science
Director, Rutgers Institute for Translational Medicine & Science
New Brunswick, New Jersey
Emeritus Professor of Medicine
University of Pennsylvania
Philadelphia, Pennsylvania
Conflict of Interest Policy/Disclosure Statement
Integrity Continuing Education requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:
Reynold A. Panettieri, Jr., MD
Consulting Fees: AstraZeneca, MedImmune, RIFM, Equillium, Theravance
Speakers’ Bureaus: AstraZeneca, Sanofi, Genentech
Contracted Research: AstraZeneca, MedImmune, RIFM, Genentech, OncoArendi
Patima Tanapat, PhD, hereby states that she or her spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
Accreditation Statement
Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Designation of Credit
Integrity Continuing Education, Inc. designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Instructions for Receiving Credit
There are no fees for participating and receiving CME credit for this activity. During the period of July 22, 2020 through July 22, 2021, participants must:
- Read the learning objectives and faculty disclosures
- Complete the pretest
- Study the educational activity
- Complete the posttest and the evaluation form
A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. and Sanofi Genzyme and Regeneron Pharmaceuticals do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
The information provided in this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient's medical condition.
Contact Information for Questions About the Activity
For information about ACCME accreditation of this activity, please contact Integrity Continuing Education at (855) 835-4004 or info@integrityce.com.
Statement of Commercial Support
Supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.